Charles Schwab
DFTX

Charles Schwab’s Definium Therapeutics DFTX Stock Holding History

Charles Schwab’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51M Buy
1,083,576
+274,861
+34% +$6.79M 0.01% 1224
2026
Q1 		$15.3M Buy
808,715
+1,466
+0.2% +$24.9K ﹤0.01% 1891
2025
Q4 		$10.8M Buy
807,249
+173,547
+27% +$2.15M ﹤0.01% 2097
2025
Q3 		$7.47M Buy
633,702
+35,490
+6% +$331K ﹤0.01% 2255
2025
Q2 		$3.88M Buy
598,212
+34,908
+6% +$230K ﹤0.01% 2434
2025
Q1 		$3.3M Sell
563,304
-30,052
-5% -$215K ﹤0.01% 2447
2024
Q4 		$4.13M Sell
593,356
-9,188
-2% -$63.2K ﹤0.01% 2421
2024
Q3 		$3.43M Buy
602,544
+46,187
+8% +$321K ﹤0.01% 2541
2024
Q2 		$4.01M Buy
556,357
+359,143
+182% +$3.14M ﹤0.01% 2432
2024
Q1 		$1.85M Buy
197,214
+5,340
+3% +$30.4K ﹤0.01% 2617
2023
Q4 		$702K Buy
191,874
+3,338
+2% +$10.1K ﹤0.01% 2950
2023
Q3 		$590K Buy
188,536
+8,727
+5% +$35.9K ﹤0.01% 2985
2023
Q2 		$642K Buy
179,809
+859
+0.5% +$2.96K ﹤0.01% 2931
2023
Q1 		$567K Sell
178,950
-2,517
-1% -$8.37K ﹤0.01% 2910
2022
Q4 		$399K Buy
+181,467
New +$504K ﹤0.01% 3056
2022
Q2 		– Sell
-47,904
Closed -$798K – 3607
2022
Q1 		$798K Sell
47,904
-2,055
-4% -$35.7K ﹤0.01% 2941
2021
Q4 		$1.03M Buy
49,959
+822
+2% +$26.2K ﹤0.01% 2900
2021
Q3 		$1.72M Buy
49,137
+3,617
+8% +$156K ﹤0.01% 2734
2021
Q2 		$2.36M Buy
+45,520
New +$2.39M ﹤0.01% 2660

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Charles Schwab's DFTX Position: Q2 2026 in Review

Charles Schwab increased its Definium Therapeutics (DFTX) stake by 34% in Q2 2026, buying an estimated $6.79M and bringing the position to 1,083,576 shares worth $51M. The position accounts for 0.01% of the portfolio, ranked #1224.

Charles Schwab first reported a position in DFTX in Q2 2021 and has held it in 19 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Charles Schwab held 1,083,576 shares of Definium Therapeutics worth $51M as of Q2 2026.
  • Charles Schwab bought 274,861 Definium Therapeutics shares in Q2 2026, an estimated $6.79M.
  • Definium Therapeutics made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1224 holding.
  • Charles Schwab first reported a position in Definium Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.